{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:27:31Z","timestamp":1791235651708,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.addr.2022.114142","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T10:53:46Z","timestamp":1644404026000},"page":"114142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Toward rational vaccine engineering"],"prefix":"10.1016","volume":"183","author":[{"given":"Yashavantha L.","family":"Vishweshwaraiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-4025","authenticated-orcid":false,"given":"Nikolay V.","family":"Dokholyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114142_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2022.114142_b0010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2022.114142_b0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri3694","article-title":"From empiricism to rational design: A personal perspective of the evolution of vaccine development","volume":"14","author":"De Gregorio","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2022.114142_b0020","unstructured":"T.W. Mak, M.E. Saunders, B.D.B.T.-P. to the I.R., in: Second E. Jett (Eds.), Chapter 14 - Vaccination, in: Academic Cell, Boston, 2014, pp. 333\u2013375. http:\/\/dx.doi.10.1016\/B978-0-12-385245-8.00014-5."},{"key":"10.1016\/j.addr.2022.114142_b0025","article-title":"The genome revolution in vaccine research","volume":"6","author":"Capecchi","year":"2004","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.addr.2022.114142_b0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2022.114142_b0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jmv.25593","article-title":"Why are vaccines against many human viral diseases still unavailable; an historic perspective?","volume":"92","author":"Tannock","year":"2020","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.addr.2022.114142_b0040","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1172\/JCI38330","article-title":"Vaccinology in the genome era","volume":"119","author":"Rinaudo","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2022.114142_b0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","article-title":"Structure-based antigen design: a strategy for next generation vaccines","volume":"26","author":"Dormitzer","year":"2008","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2022.114142_b0050","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fmicb.2019.00738","article-title":"structural vaccinology for viral vaccine design","volume":"10","author":"Anasir","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114142_b0055","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology."},{"key":"10.1016\/j.addr.2022.114142_b0060","doi-asserted-by":"crossref","unstructured":"S. Bhardwaj, in: D. Vohora, G.B.T.-P.M., T.C.R. Singh (Eds.), Chapter 21 - Vaccines, Academic Press, Boston, 2018, pp. 341\u2013353. http:\/\/dx.doi.10.1016\/B978-0-12-802103-3.00022-5.","DOI":"10.1016\/B978-0-12-802103-3.00022-5"},{"key":"10.1016\/j.addr.2022.114142_b0065","article-title":"Vaccines: Present status and applications","author":"Yadav","year":"2013","journal-title":"Elsevier"},{"key":"10.1016\/j.addr.2022.114142_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2022.114142_b0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J. Glob. Infect. Dis."},{"key":"10.1016\/j.addr.2022.114142_b0080","first-page":"45","article-title":"Inactivated viral vaccines, Vaccine Anal","author":"Sanders","year":"2014","journal-title":"Strateg. Princ. Control."},{"issue":"2","key":"10.1016\/j.addr.2022.114142_b0085","first-page":"353","article-title":"Development of vaccine formulations: past, present, and future, Drug Deliv","volume":"11","author":"D\u2019Amico","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2022.114142_b0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"issue":"11","key":"10.1016\/j.addr.2022.114142_b0095","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1586\/14760584.2013.840092","article-title":"Vaccines based on structure-based design provide protection against infectious diseases","volume":"12","author":"Thomas","year":"2013","journal-title":"Expert Rev. Vaccines."},{"issue":"12","key":"10.1016\/j.addr.2022.114142_b0100","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2022.114142_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology."},{"issue":"9","key":"10.1016\/j.addr.2022.114142_b0110","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2022.114142_b0115","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0264-410X(99)00351-5","article-title":"HPV6b virus like particles are potent immunogens without adjuvant in man","volume":"18","author":"Zhang","year":"2000","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.addr.2022.114142_b0120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/CMR.8.3.406","article-title":"Nucleic acid vaccines","volume":"8","author":"Vogel","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2022.114142_b0125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","article-title":"Recent developments and future possibilities","volume":"17","author":"Liu","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2022.114142_b0130","first-page":"1","article-title":"A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications, Front. Cell","volume":"9","author":"Qin","year":"2021","journal-title":"Dev. Biol."},{"issue":"12","key":"10.1016\/j.addr.2022.114142_b0135","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"4","key":"10.1016\/j.addr.2022.114142_b0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114142_b0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cei.13287","article-title":"Novel approaches for the design, delivery and administration of vaccine technologies","volume":"196","author":"Wallis","year":"2019","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.addr.2022.114142_b0150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114142_b0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114142_b0160","series-title":"mRNA Cancer Vaccines\u2014Messages that Prevail BT - Cancer Vaccines","first-page":"145","author":"Grunwitz","year":"2017"},{"issue":"3","key":"10.1016\/j.addr.2022.114142_b0165","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2022.114142_b0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2022.114142_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/v13020317","article-title":"Viral vectors for covid-19 vaccine development","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses."},{"issue":"9","key":"10.1016\/j.addr.2022.114142_b0180","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2022.114142_b0185","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2022.114142_b0190","article-title":"What are the most powerful immunogen design vaccine strategies? reverse vaccinology 2.0 shows great promise, Cold Spring Harb","volume":"9","author":"Burton","year":"2017","journal-title":"Perspect. Biol."},{"issue":"1","key":"10.1016\/j.addr.2022.114142_b0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","article-title":"Advances in antiviral vaccine development","volume":"255","author":"Graham","year":"2013","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.addr.2022.114142_b0200","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/21645515.2019.1670035","article-title":"Shukla, Computational tools for modern vaccine development","volume":"16","author":"Sunita","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2022.114142_b0205","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B Vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2022.114142_b0210","first-page":"108","article-title":"History of polio vaccination, World","volume":"1","author":"Baicus","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2022.114142_b0215","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/156241","article-title":"Structural and computational biology in the design of immunogenic vaccine antigens","volume":"2015","author":"Liljeroos","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.addr.2022.114142_b0220","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/B978-012088451-3.50024-7","article-title":"Immunity to Pathogens","author":"Mak","year":"2006","journal-title":"The Immune Response."},{"issue":"5","key":"10.1016\/j.addr.2022.114142_b0225","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114142_b0230","first-page":"13","article-title":"Epitope mapping of antibody-antigen interactions with x-ray crystallography, Methods Mol","author":"Toride King","year":"1785","journal-title":"Biol."},{"key":"10.1016\/j.addr.2022.114142_b0235","doi-asserted-by":"crossref","first-page":"13577","DOI":"10.1038\/ncomms13577","article-title":"Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses","volume":"7","author":"Wang","year":"2016","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.addr.2022.114142_b0240","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cell.2015.08.035","article-title":"Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env","volume":"162","author":"Scharf","year":"2015","journal-title":"Cell."},{"key":"10.1016\/j.addr.2022.114142_b0245","doi-asserted-by":"crossref","first-page":"e1006935","DOI":"10.1371\/journal.ppat.1006935","article-title":"Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies","volume":"14","author":"Jones","year":"2018","journal-title":"PLoS Pathog."},{"issue":"2019","key":"10.1016\/j.addr.2022.114142_b0250","first-page":"D339","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2022.114142_b0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00063030-200721030-00002","article-title":"Epitope mapping: the first step in developing epitope-based vaccines","volume":"21","author":"Gershoni","year":"2007","journal-title":"BioDrugs."},{"issue":"6","key":"10.1016\/j.addr.2022.114142_b0260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jmr.2454","article-title":"Epitope mapping by solution NMR spectroscopy","volume":"28","author":"Bardelli","year":"2015","journal-title":"J. Mol. Recognit."},{"issue":"4","key":"10.1016\/j.addr.2022.114142_b0265","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0969-2126(00)00119-2","article-title":"NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding","volume":"8","author":"Tugarinov","year":"2000","journal-title":"Structure."},{"key":"10.1016\/j.addr.2022.114142_b0270","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.3390\/ijms160613106","article-title":"Protein crystallography in vaccine research and development","volume":"16","author":"Malito","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"7815","key":"10.1016\/j.addr.2022.114142_b0275","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.addr.2022.114142_b0280","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","article-title":"Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization","volume":"52","author":"Gilchuk","year":"2020","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.addr.2022.114142_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12250-019-00190-5","article-title":"Cryo-EM Studies of Virus-antibody immune complexes","volume":"35","author":"Li","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.addr.2022.114142_b0290","series-title":"Prediction of conformational B-Cell Epitopes","first-page":"185","author":"Zhang","year":"2014"},{"issue":"7873","key":"10.1016\/j.addr.2022.114142_b0295","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature."},{"key":"10.1016\/j.addr.2022.114142_b0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coi.2020.03.013","article-title":"Innovations in structure-based antigen design and immune monitoring for next generation vaccines","volume":"65","author":"Ward","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2022.114142_b0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159709","article-title":"Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus","volume":"11","author":"Boyington","year":"2016","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.addr.2022.114142_b0310","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope","volume":"25","author":"Bajic","year":"2019","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.addr.2022.114142_b0315","doi-asserted-by":"crossref","first-page":"eaax4380","DOI":"10.1126\/science.aax4380","article-title":"A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses","volume":"366","author":"Steichen","year":"2019","journal-title":"Science."},{"issue":"17","key":"10.1016\/j.addr.2022.114142_b0320","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.1128\/JVI.76.17.8875-8889.2002","article-title":"Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1","volume":"76","author":"Sanders","year":"2002","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.addr.2022.114142_b0325","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nsmb.3051","article-title":"Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env","volume":"22","author":"Do Kwon","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6158","key":"10.1016\/j.addr.2022.114142_b0330","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114142_b0335","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.addr.2022.114142_b0340","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.coviro.2013.05.010","article-title":"Advances in structure-based vaccine design","volume":"3","author":"Kulp","year":"2013","journal-title":"Curr. Opin. Virol."},{"issue":"7491","key":"10.1016\/j.addr.2022.114142_b0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.addr.2022.114142_b0350","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1080\/21645515.2016.1160977","article-title":"The promise and challenge of epitope-focused vaccines","volume":"12","author":"Oscherwitz","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.addr.2022.114142_b0355","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","article-title":"Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus","volume":"409","author":"McLellan","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"42","key":"10.1016\/j.addr.2022.114142_b0360","doi-asserted-by":"crossref","first-page":"17880","DOI":"10.1073\/pnas.1004728107","article-title":"Elicitation of structure-specific antibodies by epitope scaffolds","volume":"107","author":"Ofek","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.addr.2022.114142_b0365","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jmb.2011.10.003","article-title":"Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope","volume":"415","author":"Azoitei","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.addr.2022.114142_b0370","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.str.2010.06.010","article-title":"Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope","volume":"18","author":"Correia","year":"2010","journal-title":"Structure."},{"issue":"6054","key":"10.1016\/j.addr.2022.114142_b0375","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1209368","article-title":"Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold","volume":"334","author":"Azoitei","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114142_b0380","first-page":"1","article-title":"Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies","volume":"10","author":"Zhu","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.addr.2022.114142_b0385","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/bioinformatics\/btr129","article-title":"Rigid substructure search","volume":"27","author":"Shirvanyants","year":"2011","journal-title":"Bioinformatics."},{"issue":"7","key":"10.1016\/j.addr.2022.114142_b0390","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.str.2008.03.013","article-title":"Ab initio folding of proteins with all-atom discrete molecular dynamics","volume":"16","author":"Ding","year":"2008","journal-title":"Structure."},{"key":"10.1016\/j.addr.2022.114142_b0395","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nmeth0607-466","article-title":"Eris: an automated estimator of protein stability","volume":"4","author":"Yin","year":"2007","journal-title":"Nat. Methods."},{"issue":"5","key":"10.1016\/j.addr.2022.114142_b0400","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1021\/acsinfecdis.0c00008","article-title":"Structure-guided molecular grafting of a complex broadly neutralizing viral epitope","volume":"6","author":"Bajic","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.addr.2022.114142_b0405","article-title":"Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif","author":"Hauser","year":"2021","journal-title":"BioRxiv."},{"key":"10.1016\/j.addr.2022.114142_b0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22000321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22000321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:16:01Z","timestamp":1759209361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":82,"alternative-id":["S0169409X22000321"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114142","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward rational vaccine engineering","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114142"}}